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Background: To quantify the variability among centers and to identify centers whose performance are potentially
outside of normal variability in the primary outcome and to propose a guideline that they are outliers.
Methods: Novel statistical methodology using a Bayesian hierarchical model is used. Bayesian methods for
estimation and outlier detection are applied assuming an additive random center effect on the log odds of
response: centers are similar but different (exchangeable). The Intraoperative Hypothermia for Aneurysm Surgery
Trial (IHAST) is used as an example. Analyses were adjusted for treatment, age, gender, aneurysm location, World
Federation of Neurological Surgeons scale, Fisher score and baseline NIH stroke scale scores. Adjustments for
differences in center characteristics were also examined. Graphical and numerical summaries of the between-center
standard deviation (sd) and variability, as well as the identification of potential outliers are implemented.
Results: In the IHAST, the center-to-center variation in the log odds of favorable outcome at each center is
consistent with a normal distribution with posterior sd of 0.538 (95% credible interval: 0.397 to 0.726) after adjusting
for the effects of important covariates. Outcome differences among centers show no outlying centers. Four
potential outlying centers were identified but did not meet the proposed guideline for declaring them as outlying.
Center characteristics (number of subjects enrolled from the center, geographical location, learning over time,
nitrous oxide, and temporary clipping use) did not predict outcome, but subject and disease characteristics did.
Conclusions: Bayesian hierarchical methods allow for determination of whether outcomes from a specific center
differ from others and whether specific clinical practices predict outcome, even when some centers/subgroups
have relatively small sample sizes. In the IHAST no outlying centers were found. The estimated variability between
centers was moderately large.
Keywords: Bayesian outlier detection, Between center variability, Center-specific differences, Exchangeable, Multi-
center clinical trial, Performance, SubgroupsBackground
It is important to determine if treatment effects and/or
other outcome differences exist among different partici-
pating medical centers in multicenter clinical trials.
Establishing that certain centers truly perform better or
worse than others may provide insight as to why an
experimental therapy or intervention was effective in
one center but not in another and/or whether a trial’s* Correspondence: emine-bayman@uiowa.edu
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reproduction in any medium, provided the orconclusions may have been impacted by these
differences. For multi-center clinical trials, identifying
centers performing on the extremes may also explain
differences in following the study protocol [1]. Quantify-
ing the variability between centers provides insight even
if it cannot be explained by covariates. In addition, in
healthcare management, it is important to identify med-
ical centers and/or individual practitioners who have su-
perior or inferior outcomes so that their practices can
either be emulated or improved.
Determining whether a specific medical center truly
performs better than others can be difficult and/orl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tion, has different standard of care, the sample size varies
between centers and is sometimes small. Spiegelhalter
recommended using funnel plots to compare institutional
performances [2]. Funnel plots are especially useful when
sample sizes are variable among centers. When the out-
come is binary, the good outcome rates can be plotted
against sample size as a measure of precision. In addition,
95% and 99.8% exact frequentist confidence intervals are
plotted. Centers outside of these confidence bounds are
identified as outliers. However, since confidence intervals
are very large for small centers, it is almost impossible to
detect a center with a small sample size as an outlier or
potential outlier using frequentist methods.
Bayesian hierarchical methods can address small sam-
ple sizes by combining prior information with the data
and making inferences from the combined information.
The Bayesian hierarchical model borrows information
across centers and thus, accounts appropriately for small
sample sizes and leads to different results than the
frequentist approach without a hierarchical mixed effects
model. A frequentist hierarchical model with components
of variance could also be used and also borrows informa-
tion; however frequentist point estimates of the variance
may have large mean square errors compared to Bayesian
estimates [3].
The aim of this study is to demonstrate the application
of Bayesian methods to determine if outcome differences
exist among centers, and if differences in center-specific
clinical practices predict outcomes. The variability among
centers is also estimated and interpreted. To do so, we
utilized data from the Intraoperative Hypothermia for
Aneurysm Surgery Trial (IHAST [4]). Specifically, we
determined, using a Bayesian mixed effects model,
whether outcome variability among IHAST centers was
consistent with a normal distribution and/or whether out-
come differences can be explained by characteristics of
the centers, the patients, and/or specific clinical practices
of the various centers.
Methods
Frequentist IHAST methods
IHAST was a prospective randomized partially blinded
multicenter clinical trial (1001 subjects, 30 centers) de-
signed to determine whether mild intraoperative systemic
hypothermia (33°C), compared to normothermia (36.5°C),
resulted in improved neurologic outcome in subjects with
an acute subarachnoid hemorrhage (SAH) undergoing sur-
gery (open craniotomy) to treat a ruptured intracranial
aneurysm [4]. A large number of subject and clinical
variables were recorded prior to randomization including
age, gender, race, World Federation of Neurological
Surgeons (WFNS) class, amount of subarachnoid blood
(Fisher score), aneurysm size and location, and pre SAH-medical conditions. The details and results of the primary
study [4], and subsequent secondary analyses have been
previously published [5-9]. The primary outcome measure
was the modified Glasgow Outcome Score (GOS)
determined 3 months after surgery. The GOS is a five-
point functional outcome scale which ranges between 1
(good outcome) and 5 (death) [10]. The primary result of
IHAST was that intraoperative hypothermia did not affect
neurological outcome: 66% (329 / 499) good outcome
(GOS = 1) with hypothermia vs. 63% (314 / 501) good out-
come with normothermia, odds ratio (OR) = 1.15, 95%
confidence interval: 0.89 to 1.49 [4].
In IHAST, the randomized treatment assignment
(intraoperative hypothermia vs. normothermia) was strati-
fied by center such that approximately equal numbers of
patients were randomized to hypothermia and normo-
thermia at each participating center. The number of
patients contributed by each center ranged between 3 and
93 (median = 27 patients). A conventional funnel plot
showing the proportion of patients with good outcomes
by center vs. the number of patients contributed by those
centers is implemented.
Bayesian methods in general
Bayesian inference interprets probability as a degree of
belief, and unknown parameters are random variables
with prior probability distributions. For example, in
IHAST a prior belief was held that the probability of a
good outcome would be around 70% and this probability
might range from as low as 30% in one center and as
high as 90% in another. This information is used to con-
struct the prior distribution of the between-center vari-
ance. Bayesian methods require that careful attention is
paid to the choice of prior distribution [11] and a sensi-
tivity analysis is recommended [12].
The Bayesian approach combines prior information
with the clinical trial data and makes inference from this
combined information [11,13]. Accordingly, when new
clinical trial data become available, the probability
distributions are updated, using Bayes theorem, to give a
posterior distribution. In contrast, in the traditional
approach, probability is interpreted as a long run
frequency, giving rise to the terminology “frequentist”
inference.
Bayesian methods applied to the IHAST trial
A Bayesian hierarchical generalized linear model was
used for the log odds of a good outcome (defined as a
3-month GOS score of 1). The center effects are addi-
tive in the log odds of a good outcome at the different
centers and are assumed to be randomly sampled from
a normal population; hence they are expected to be
different in each center, but similar. In probabilistic
terms, this property of “different but similar” is defined
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sumption, it is assumed a priori that good outcome rates
for all centers are a sample from the same distribution,
and beliefs are invariant to ordering or relabeling of the
centers. With the hierarchical model assumption, each
center borrows information from the corresponding data
of other centers [16]. This is called a shrinkage effect to-
wards the population mean and, as will be shown, this
can be especially beneficial when there are small sample
sizes in some centers.
As in all prior IHAST publications [5-9], a set of 10
standard covariates were used when exploring the im-
pact of any variable on outcome: preoperative WFNS
score (WFNS = 1 or WFNS >1), age (on the continu-
ous scale), gender, Fisher grade on first CT scan, post-
SAH National Institute of Health Stroke Scale score
(NIHSS), aneurysm location (posterior vs anterior),
race, aneurysm size, history of hypertension, and inter-
val from SAH to surgery. These were chosen because
of either their demonstrated association with outcome
in IHAST or because previous studies had shown
them to be associated with outcome following SAH.
This set of covariates is included as predictor
variables as is treatment assignment (hypothermia vs.
normothermia).
In the IHAST 1001 patients were enrolled and
randomized, with complete data and follow up is avail-
able on 940 subjects. The data set for the 940 subjects is
therefore used here.
Let njk denote the number of subjects assigned to
treatment j in center k and Xijk be the values of the
covariates for the ith subject in the jth treatment
group at the kth center (i = 1,. . .,njk, j = 1,2, k =
1,. . .,30). Let yijk = 1 denote a good outcome (GOS =
1) for ith subject in jth treatment in center k and yijk
= 0 denote GOS >1 for the same subject. Also let

β
be the vector of covariates including the intercept μ
and coefficients β1 to β11 for treatment assignment
and the 10 standard covariates given previously.
Conditional on the linear predictor

xT
i 
β and the ran-
dom center effect δk , yijk are Bernoulli random
variables. Denote the probability of a good outcome,
yijk = 1, to be pijk. The random center effects (δk, k =
1,. . .,30) conditional on the value σe are assumed to be
a sample from a normal distribution with a mean of
zero and sd σe . This assumption makes them ex-
changeable: δk | σe ~ Normal (0, σ
2
e). The value σe is the
between-center variability on the log odds scale. The
point estimate of σe is denoted by s. The log odds of a good
outcome for subject i assigned to treatment j in center k
are denoted by θijk = logit(pijk) = log(pijk/(1 – pijk)) (i = 1,. . .,
njk, j = 1,2, k = 1,. . .,30).A model with all potential covariates is θijk ¼

xT
i 
βþ δk
and can also be written as follows:
θijk ¼ μþ β1treatmentj þ β2WFNSi þ β3agei
þβ4genderi þ β5fisheri þ β6strokei
þβ7locationi þ β8racei þ β9sizei
þβ10hypertensioni þ β11intervali þ δk
where μ is the intercept in the logit scale: β1 to β11 are
coefficients to adjust for treatment and 10 standard
covariates that are given previously and in Appendix
A.1.
Backward model selection is applied to detect import-
ant covariates associated with good outcome [17,18].
Covariates are deemed important by checking whether
the posterior credible interval of slope term excludes
zero. Models are also compared based on their deviance
information criteria (DIC) [19]. DIC is a single number
describing the consistency of the model to the data. A
model with the smaller DIC represents a better fit (see
Appendix A.2). Once the important main effects are
found, the interaction terms for the important main
effects are examined. A model is also fit using all the
covariates.
Prior distributions modified from Bayman et al. [20]
are used and a sensitivity analysis is performed. Prior
distributions for the overall mean and coefficients for
the fixed effects are not very informative (see Appendix
A.3). The prior distribution of the variance σe
2 is inform-
ative and is specified as an inverse gamma distribution
(see Appendix A.3) using the expectations described
earlier. Values of σe close to zero represent greater
homogeneity of centers.
The Bayesian analysis calculates the posterior distribu-
tion of the between-center standard deviation, diagnostic
probabilities for centers corresponding to “potential
outliers”, and graphical diagnostic tools. Posterior point
estimates and center- specific 95% credible intervals (CI)
of random center effects (δk) are calculated. A guideline
based on interpretation of a Bayes Factor (BF) [14] is
proposed for declaring a potential outlier “outlying”. Sen-
sitivity to the prior distribution is also examined [19].
Specific bayesian methods to determine outlying centers
The method in Chaloner [21] is used to detect outlying
random effects. The method extends a method for a
fixed effects linear model [22]. The prior probability of
at least one center being an outlier is set to 0.05, and be-
cause there are 30 centers, this leads to a definition of
an outlying center as one where the magnitude of the
random center effect, δk, is greater than 3.137σe in abso-
lute value (Appendix A.4). The corresponding prior
probability of a specific center being an outlier is 0.0017:
Bayman et al. BMC Medical Research Methodology 2013, 13:5 Page 4 of 12
http://www.biomedcentral.com/1471-2288/13/5Pr(center k is an outlier) = 2 *Φ(−3.137) [22], where Φ(z)
is the standard normal distribution function.
The posterior probabilities of center k being an outlier:
Pr(center k is an outlier | y) are calculated from the joint
posterior distribution of δk and σe [22]. The Bayes factor
is also calculated for each of the 30 centers to quantify
and interpret the strength of evidence. The BF for center
k is defined as follows:
BFk ¼ ½1 Pr center k is an outlier yj Þð Pr center k is an outlierð ÞPr center k is an outlier yj Þ 1 Pr center k is an outlierð Þ½ :ð
The BF for at least one of the 30 centers being an out-
lier is also calculated. The proposed method for
interpreting the results is that centers where the poster-
ior probability of being an outlier is larger than the prior
probability are “potential outliers”. In addition, if BFk is
less than 0.316 then there is “substantial evidence” for
center k being outlying [14]. Similarly if the BF for there
being at least one outlying center is less than 0.316 there
is substantial evidence for at least one outlying center.
Bayesian methods regarding other determinants of
outcome
In addition to determining if the treatment effect
(hypothermia vs. normothermia) differed among any of the
30 IHAST centers and to illustrate our approach on differ-
ent settings, Bayesian outlier detection methods were ap-
plied to determine whether other center-specific subgroups
(e.g. number of subjects, geographic location, various clin-
ical practices like nitrous oxide use and temporary clip-
ping) had an effect on outcome (GOS 1 vs. GOS >1).
To determine if the number of subjects enrolled at a
center predicted outcome, IHAST centers were
categorized post hoc by number of enrolled subjects. Let
nk = n1k + n2k and classify centers as either very large (nk≥
69 subjects; 3 centers, 248 subjects), large (56≤ nk≤ 68
subjects; 4 centers, 228 subjects), medium (31≤ nk≤ 55
subjects, 7 centers, 282 subjects)) and small (nk < 31 subjects,
16 centers, 242 subjects). To determine if geographic loca-
tion predicted outcome, IHAST centers were categorized
post hoc as being either North American (US and Canada,
22 centers, 637 subjects) or non-North American (Europe,
Australia, New Zealand, 8 centers, 363 subjects). To deter-
mine if there was evidence of “learning” over the entire
course of the study, outcomes of the first 50% of subjects en-
rolled in the study (all centers) were compared with
outcomes from the second 50% of subjects enrolled (all
centers). Similarly, within each center, the outcomes of first
50% subjects were compared to the second 50%.
There are a number of clinical practices which vary
among centers that are hypothesized, but not proven, to
affect outcome in patients with aneurysmal subarachnoid
hemorrhage, such as electrophysiological monitoring,electroencephalography or somatosensory evoked po-
tentials [23], nitrous oxide use [5], temporary clipping
[6], etc. Centers and/or individual practitioners tend to
either embrace these practices (high use) or reject them
(low use). Accordingly, Bayesian techniques were used to
examine the clinical effect of one anesthetic practice (ni-
trous oxide use) and one surgical practice (temporary
clipping). To determine if the frequency of nitrous oxide
use affected outcome, centers were categorized as to
their use of nitrous oxide as either low (≤25% of the
cases, 13 centers), medium (26% to 74% of cases, 8
centers) or high (≥75% of cases, 9 centers). In addition,
the effect of the nitrous oxide use was explored at the in-
dividual subject level (yes, 627 subjects; no, 373 subjects).
Finally, the effect of the use of temporary clipping during
aneurysm surgery was compared among centers. Centers
were categorized as to their frequency of use of tempor-
ary clips as low: (≤30% of cases; 6 centers), medium:
(30% to 69% of cases; 21 centers) and high: (≥70% or
more of case; 3 centers). The effect of temporary clipping
at the individual subject level (yes, 441 subjects; no, 553
subjects) was also examined.
Plots are obtained by R [24], and Bayesian analyses are
performed with the WinBUGS [25] program. Model
convergence is checked by Brooks, Gelman, Rubin diag-
nostics plots [26], autocorrelations, density and history
plots. A sensitivity analysis is performed.
Results
Frequentist analysis
Figure 1 gives the funnel plot [2] for IHAST by center.
In this plot, center sizes (nk) are plotted against the pro-
portion of good outcome for each center and 95% and
99.8% exact binomial confidence intervals are provided.
The horizontal line on the funnel plot represents the
overall weighted fixed effect good outcome rate (66%).
Centers outside of the 95% and 99.8% confidence
bounds are identified as outliers. Accordingly, using this
method, IHAST centers 26 and 28 would be identified as
outliers, performing less well than the rest of the
centers, with good outcome rates of 51% and 42%, re-
spectively. However, importantly, patient and center
characteristics are not taken into account in this plot.
Bayesian analysis
A Bayesian hierarchical generalized linear model is fit
taking into account the 10 potential covariates and the
treatment effect in the model. Covariates are given earl-
ier (see also Appendix A.1). Considering all possible
models, the DIC indicates that pre-operative WFNS,
Fisher grade on CT scan, pre-operative NIH stroke scale
score, aneurysm location (anterior / posterior) and, age
should be included in the model. For completeness,
gender and treatment are also included as covariates
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Figure 1 Funnel plot, frequentist, no adjustment for other covariates.
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adjusts for the main effects of treatment (hypothermia
vs. normothermia), WFNS score, gender, Fisher grade on
CT scan, pre-operative NIHS stroke scale score,
aneurysm location (anterior /posterior), age, center and
the interaction of age and pre-operative NIH stroke
scale. In this model the log odds of a good outcome for
the ith subject assigned the jth treatment in center k is:
θijk ¼ μþ β1treatmentj þ β2WFNSi þ β3agei
þβ4genderi þ β5fisheri þ β6strokei
þβ7locationi þ β8agei  strokei þ δk
The model with the posterior means substituted as
estimates for the coefficients is:
θ^ ijk ¼ 2:024þ 0:198  treatmentj þ 0:600 WFNSi
0:037  agei  0:256  genderi þ 0:777
fisheri  0:878  strokei  0:788
locationi þ 0:027  agei  strokei þ δk
and δk is the random center effect. The posterior means
of the center effects along with 95% CI’s are given in
Figure 2.
There is no evidence of an important treatment effect
(hypothermia vs. normothermia). Centers have either
greater good outcome rates in both hypothermia and
normothermia groups, or lower good outcome rate in
both treatment groups (data is not shown). The treat-
ment effect (hypothermia vs. normothermia) within each
center was very small. It should be also noted that, whenall the potential covariates are included in the model,
the conclusions are essentially identical.
In Figure 2 centers are sorted in ascending order of
numbers of subjects randomized. For example, 3
subjects were enrolled in center 1 and 93 subjects were
enrolled in center 30. Figure 2 shows the variability be-
tween center effects. Consider a 52-year-old (average
age) male subject with preoperative WFNS score of 1,
no pre-operative neurologic deficit, pre-operative Fisher
grade of 1 and posterior aneurysm. For this subject, pos-
terior estimates of probabilities of good outcome in the
hypothermia group ranged from 0.57 (center 28) to 0.84
(center 10) across 30 centers under the best model.
The posterior estimate of the between-center sd (σe) is
s = 0.538 (95% CI of 0.397 to 0.726) which is moderately
large. The horizontal scale in Figure 2 shows ± s, ±2 s
and ±3 s. Outliers are defined as center effects larger
than 3.137σe and posterior probabilities of being an out-
lier for each center are calculated. Any center with a
posterior probability of being an outlier larger than the
prior probability (0.0017) would be suspect as a potential
outlier. Centers 6, 7, 10 and 28 meet this criterion;
(0.0020 for center 6, 0.0029 for center 7, 0.0053 for cen-
ter 10, and 0.0027 for center 28). BF’s for these four
centers are 0.854, 0.582, 0.323 and 0.624 respectively.
Using the BF guideline proposed (BF < 0.316) the hy-
pothesis is supported that they are not outliers [14]; all
BF’s are interpreted as “negligible” evidence for outliers.
The prior probability that at least one of the 30 centers
is an outlier is 0.05. The joint posterior probability that
at least one of the 30 centers is an outlier is 0.019, which
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Figure 2 Posterior mean and 95% CIs of center log odds of good outcome (GOS = 1) for each center are presented under the final
model. Posterior center log odds of good outcome greater than 0 indicates more good outcomes are observed in that center. Horizontal lines
show ± s, ±2 s and ±3 s, where s is the posterior mean of the between-center standard deviation (s = 0.538, 95% CI: 0.397 to 0.726). Centers are
ordered by enrollment size.
Bayman et al. BMC Medical Research Methodology 2013, 13:5 Page 6 of 12
http://www.biomedcentral.com/1471-2288/13/5is less than the prior probability of 0.05. Both individual
and joint results therefore lead to the conclusion that
the no centers are identified as outliers.
Under the normality assumption, the prior probability
of any one center to be an outlier is low and is 0.0017
when there are 30 centers. In this case, any center with a
posterior probability of being an outlier larger than
0.0017 would be treated as a potential outlier. It is there-
fore possible to identify a center with a low posterior
probability as a “potential outlier”. The Bayes Factor
(BF) can be used to quantify whether the relative change
from the prior probability of being outlier to the poster-
ior probability is large enough to categorize a center as
an outlier.
The use of Bayesian analysis methods demonstrates
that, although there is center to center variability, after
adjusting for other covariates in the model, none of the
30 IHAST centers performed differently from the other
centers more than is expected under the normal distri-
bution. Without adjusting for other covariates, and with-
out the exchangeability assumption, the funnel plot
indicated two IHAST centers were outliers. When other
covariates are taken into account together with the
Bayesian hierarchical model those two centers were not,in fact, identified as outliers. The less favorable
outcomes in those two centers were because of
differences in patient characteristics (sicker and/or older
patients).
Subgroup analysis
When treatment (hypothermia vs. normothermia),
WFNS, age, gender, pre-operative Fisher score, pre-
operative NIH stroke scale score, aneurysm location and
the interaction of age and pre-operative NIH stroke scale
score are in the model and similar analyses for outcome
(GOS1 vs. GOS > 1) are performed for four different cat-
egories of center size (very large, large, medium, and
small) there is no difference among centers—indicating
that patient outcomes from centers that enrolled greater
numbers of patients were not different than outcomes
from centers that enrolled the fewer patients. Our ana-
lysis also shows no evidence of a practice or learning
effect—the outcomes of the first 50% of patients did not
differ from the outcomes of the second 50% of patients,
either in the trial as a whole or in individual centers.
Likewise, an analysis of geography (North American vs.
Non-North American centers) showed that outcomes
were homogeneous in both locations. The analysis of
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use (low, medium or high user centers, and on the pa-
tient level) and temporary clip use (low, medium, or
high user centers and on the patient level) also found
that differences were consistent with a normal variability
among those strata. This analysis indicates that, overall,
differences among centers—either in their size, geography,
and their specific clinical practices (e.g. nitrous oxide use,
temporary clip use) did not affect patient outcome.Sensitivity analysis
As a sensitivity analysis, Figure 3 shows the posterior
density plots of between-center standard deviation, σe,
for each of 15 models fit. For the first four models, when
non important main effects of race, history of hyperten-
sion, aneurysm size and interval from SAH to surgery
are in the model, s is around 0.55. The point estimate s
is consistently around 0.54 for the best main effects
model and the models including the interaction terms of
the important main effects. In conclusion, the variability
between centers does not depend much on the
covariates that are included in the models.
When other subgroups (center size, order of enroll-
ment, geographical location, nitrous oxide use and tem-
porary clip use) were examined the estimates of between
subgroup variability were similarly robust in the
corresponding sensitivity analysis.
In summary, the observed variability among centers in
IHAST has a moderately large standard deviation (σe =
0.538, 95% credible interval for σe 0.397 to 0.726). No
center was declared an outlier and no center-specific or4.02.00.0
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Figure 3 The posterior density plot of the between-center standard d
treatment, age, gender, perioperative WFNS score, baseline NIHHS sc
location, aneurysm size, interval from SAH to surgery, and center.other subgroups were associated with outcome. Sensitiv-
ity analyses give similar results.
Discussion
Although IHAST centers differed in geographic location,
experience, and in clinical practices, none of these
differences were associated with important differences in
outcome. This suggests that although there is moder-
ately large variability among centers, center-specific
variations in patient management (specifically, nitrous
oxide use or temporary clipping) did not greatly affect
outcome. If variations in patient management affected
outcome, it would be expected that centers with higher
enrollment would, as a result of learning, have better
outcomes. However, they did not. Likewise, if clinical
practices affected outcome, one would expect that
outcomes would improve over time as a result of
learning. However, our results showed that learning (first
50% vs last 50% of subjects to enroll) did not occur and
the magnitude of enrollment did not impact outcome.
Outcome was however determined in part by patient
characteristics such as WFNS, age, pre-operative Fisher
score, pre-operative NIHSS stroke scale score, and
aneurysm location. Although centers differ in their size,
location, and clinical practices, the disease and/or pa-
tient characteristics predict patient outcome in this
condition.
The greatest advantage of Bayesian techniques over
non-hierarchical frequentist methods is its ability to ad-
dress small sample sizes in some centers. When the
stratum-specific sample sizes are small, the hierarchical
Bayesian method is especially helpful because0.18.06.0
igma.e for All Models
eviation, σe, for 15 models with variables selected from
ore, history of hypertension, Fisher grade on CT scan, aneurysm
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for a particular center, and weight put on the center spe-
cific data proportional to the sample size in the center.
Consequently, centers with fewer subjects have less
weight put on their center-specific data than do centers
with more subjects. Infinite estimates and unbounded
confidence intervals arise using only data from subjects
in each center to and a frequentist fixed effects model
estimate center specific effects, but are avoided using
the Bayesian hierarchical model. For example, center 1
enrolled only three subjects: two in the hypothermia
group and one in the normothermia group. In the
hypothermia group, both patients had an unfavorable
outcome, and in the normothermia group the single pa-
tient had a good outcome. In this case, the frequentist
estimate of the log odds of good outcome for center 1
using only the data from center 1 is infinite and has ir-
regular properties. An alternative practice to avoid infin-
ite estimates is to combine small centers, or to exclude
centers with all good outcomes or unfavorable from the
analysis [27]. This approach detracts from most
preplanned statistical analyses and may reduce the
effective sample size. For an intention-to-treat analysis it
is essential to include all centers. With the Bayesian
approach, and an exchangeability assumption, center
estimates are averaged with the overall mean estimate
ignoring centers [19]. Extreme center results are there-
fore systematically adjusted towards the overall average
results. As can be seen from Figure 2, the Bayesian esti-
mate of the posterior log odds of good outcome for cen-
ter 1 uses information from all other centers and has a
much narrow range than the frequentist confidence
interval. Even if 100% good outcome rate is observed in
center 1, this center is not identified as an outlier center
because of the small sample size in this center (n = 3).
This center does not stand alone and the center-specific
estimate borrowed strength from other centers and
shifted towards the overall mean.
In the IHAST, two centers (n26 = 57, n28 = 69) were
identified as outliers by the funnel plot but with the
Bayesian approach leading to shrinkage, and also adjust-
ment for covariates they were not declared as outliers.
Funnel plots do not adjust for patient characteristics.
After adjusting for important covariates and fitting ran-
dom effect hierarchical Bayesian model no outlying
centers were identified.
With the Bayesian approach, small centers are
dominated by the overall mean and shrunk towards the
overall mean and they are harder to detect as outliers
than centers with larger sample sizes. A frequentist
mixed model could also potentially be used for a hier-
archical model. Bayman et al. [20] shows by simulation
that in many cases the Bayesian random effects models
with the proposed guideline based on BF and posteriorprobabilities typically has better power to detect outliers
than the usual frequentist methods with random effects
model but at the expense of the type I error rate.
Prior expectations for variability between centers
existed. Not very informative prior distributions for the
overall mean, and covariate parameters with an inform-
ative distribution on σe are used.
The approach proposed in this study is applicable to
multiple centers, as well as to any other stratification
(group or subgroup) to examine whether outcomes in
strata are different. Anesthesia studies are generally
conducted in a center with multiple anesthesia providers
and with only a few subjects per provider. The approach
proposed here can also be used to compare the good
outcome rates of anesthesia providers when the outcome
is binary (good vs. poor, etc.). This small sample size
issue increases the advantage of using Bayesian methods
instead of traditional frequentist methods. An additional
application of this Bayesian method is to perform a
meta-analysis, where the stratification is by study [28].
Conclusion
The proposed Bayesian outlier detection method in the
mixed effects model adjusts appropriately for sample size
in each center and other important covariates. Although
there were differences among IHAST centers, these
differences are consistent with the random variability of a
normal distribution with a moderately large standard devi-
ation and no outliers were identified. In addition, no evi-
dence was found for any known center characteristic to
explain the variability. This methodology could prove use-
ful for other between-centers or between-individuals
comparisons, either for the assessment of clinical trials or
as a component of comparative-effectiveness research.
Appendix A: Statistical appendix
A.1. List of potential covariates
The potential covariates and their definitions are:
treatment (hypothermia vs normothermia), preoperative
WFNS score(1 vs >1), age, gender, race (white vs others),
Fisher grade on CT scan (1 vs others), pre-operative
NIH stroke scale score (0 vs others), aneurysm location
(posterior vs anterior), aneurysm size (largest diameter
of first aneurysm ≥ 25 vs <25), history of hypertension
(yes vs no) and interval from SAH to surgery (0 to 7 days
vs 8 to 14 days).
A.2. Deviance Information Criterion (DIC)
The expected predicted deviance is suggested as a
measure of model comparison and adequacy to compare
the fit of different models to the same data [18,19]. The
deviance information criterion (DIC) is the difference
between the estimated average discrepancy and the dis-
crepancy of the point estimate and is a single number.
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A.3. Justification and Description of Prior Distributions
Prior distributions for the overall mean (μ), main
effects of treatment, coefficient corresponding to pre-
operative WFNS score, gender, race, Fisher grade on CT
scan, pre-operative NIH stroke scale score, aneurysm lo-
cation, aneurysm size, history of hypertension and inter-
val from SAH to surgery are assumed to be a normal
distribution with mean zero and standard deviation 10.
This distribution is not very informative. Because age is
measured in years, and has a wider scale, the prior
distribution for the regression coefficient of age at
randomization is a normal distribution centered zero
with standard deviation 1. Similarly, the prior distribu-
tion for the coefficient corresponding to interaction of
age by any other covariate is normally distributed with
mean zero and a standard deviation of 1.
As explained in the Bayesian Methods Applied to the
IHAST Trial section, the prior distribution for the
between-center variance (σe
2) is assumed to be an inverse
gamma distribution with mean 0.667 and standard devi-
ation 0.471. For this Inverse Gamma distribution, the
prior probability is 95% that any center’s log odds of a
good outcome lies between 31% and 92%. This prior
probability distribution is illustrated in Figure 4.0.0 0.2 0.4
0
1
2
3
4
Prior Probabil
0.31
Figure 4 The probability density function for σe and 95% prior probaA.4. Calculating the Prior Probability of Being an Outlier
An outlier can be defined based on specifying the prior
probability of not having any outliers as very high, say
95%. Then the prior probability of a specific center k
being an outlier when there are n centers is 2Φ(−m)
where m=Φ-1[0.5 + ½ * (0.951/n)] [22]. For example,
when comparing 30 centers, n = 30 and m is 3.137 and
the prior probability of being outlier for a specific center
is 0.0017.
A.5. Treatment and Gender as Covariates in the Final
Model
In the model selection process using the DIC criter-
ion, treatment effect is not an important covariate.
However, given that in IHAST subjects are random-
ized to treatment, hypothermia or normothermia, this
covariate is included in the final model. Similarly,
according to DIC criterion gender is not an important
covariate, however as the interaction between gen-
der and treatment effect is deemed important it is in-
cluded.
A.6. Appendix
The members of IHAST were as follows: University
of Iowa — Steering Committee: M. Todd, B. Hindman,
W. Clarke, K. Chaloner, J. Torner, P. Davis, M. Howard,
D. Tranel, S. Anderson; Clinical Coordinating Center:0.6 0.8 1.0
ity of Success
0.92
P( 0.31 < p < 0.92) = 0.95
bility interval.
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http://www.biomedcentral.com/1471-2288/13/5M. Todd, B. Hindman, J. Weeks, L. Moss, J. Winn; Data
Management Center: W. Clarke, K. Chaloner, M.
Wichman, R. Peters, M. Hansen, D. Anderson, J. Lang,
B. Yoo; Physician Safety Monitor: H. Adams; Project
Advisory Committee — G. Clifton (University of Texas,
Houston), A. Gelb (University of California, San
Francisco), C. Loftus (Temple University, Philadelphia),
A. Schubert (Cleveland Clinic, Cleveland); Physician
Protocol Monitor — D. Warner (Duke University, Dur-
ham, N.C.); Data and Safety Monitoring Board — W.
Young, chair (University of California, San Francisco), R.
Frankowski (University of Texas Health Science Center
at Houston School of Public Health, Houston), K.
Kieburtz (University of Rochester School of Medicine
and Dentistry, Rochester, N.Y.), D. Prough, University of
Texas Medical Branch, Galveston), L. Sternau (Mt. Sinai
Medical Center, Miami); NIH, National Institute of
Neurological Disease and Stroke, Bethesda, Md. — J.
Marler, C. Moy, B. Radziszewska; Participating Centers
(the number of randomized patients at each center is
listed in parentheses): Addenbrooke’s Hospital, Cam-
bridge, United Kingdom (93): B. Matta, P. Kirkpatrick,
D. Chatfield, C. Skilbeck, R. Kirollos, F. Rasulo, K. Eng-
lish, C. Duffy, K. Pedersen, N. Scurrah, R. Burnstein, A.
Prabhu, C. Salmond, A. Blackwell, J. Birrell, S. Jackson;
University of Virginia Health System, Charlottesville
(86): N. Kassell, T. Pajewski, H. Fraley, A. Morris, T.
Alden, M. Shaffrey, D. Bogdonoff, M. Durieux, Z. Zuo,
K. Littlewood, E. Nemergut, R. Bedford, D. Stone, P.
Balestrieri, J. Mason, G. Henry, P. Ting, J. Shafer, T.
Blount, L. Kim, A. James, E. Farace, L. Clark, M. Irons,
T. Sasaki, K. Webb; Auckland City Hospital, Auck-
land, New Zealand (69): T. Short, E. Mee, J. Ormrod, J.
Jane, T. Alden, P. Heppner, S. Olson, D. Ellegala, C.
Lind, J. Sheehan, M. Woodfield, A. Law, M. Harrison, P.
Davies, D. Campbell, N. Robertson, R. Fry, D. Sage, S.
Laurent, C. Bradfield, K. Pedersen, K. Smith, Y. Young,
C. Chambers, B. Hodkinson, J. Biddulph, L. Jensen, J.
Ogden, Z. Thayer, F. Lee, S. Crump, J. Quaedackers, A.
Wray, V. Roelfsema; Sozialmedizinisches Zentrum
Ost–Donauspital, Vienna (58): R. Greif, G. Kleinpeter,
C. Lothaller, E. Knosp, W. Pfisterer, R. Schatzer, C.
Salem, W. Kutalek, E. Tuerkkan, L. Koller, T. Weber, A.
Buchmann, C. Merhaut, M. Graf, B. Rapf; Harborview
Medical Center, Seattle (58): A. Lam, D. Newell, P.
Tanzi, L. Lee, K. Domino, M. Vavilala, J. Bramhall, M.
Souter, G. Britz, H. Winn, H. Bybee; St. Vincent’s Pub-
lic Hospital, Melbourne, Australia (57): T. Costello,
M. Murphy, K. Harris, C. Thien, D. Nye, T. Han, P. Mc-
Neill, B. O'Brien, J. Cormack, A. Wyss, R. Grauer, R.
Popovic, S. Jones, R. Deam, G. Heard, R. Watson, L.
Evered, F. Bardenhagen, C. Meade, J. Haartsen, J. Kruger,
M. Wilson; Universityof Iowa Health Care, Iowa City
(56): M. Maktabi, V. Traynelis, A. McAllister, P.Leonard, B. Hindman, J. Brian, F. Mensink, R. From, D.
Papworth, P. Schmid, D. Dehring, M. Howard, P.
Hitchon, J. VanGilder, J. Weeks, L. Moss, K. Manzel, S.
Anderson, R. Tack, D. Taggard, P. Lennarson, M.
Menhusen; University of Western Ontario, London,
Ont., Canada (53): A. Gelb, S. Lownie, R. Craen, T.
Novick, G. Ferguson, N. Duggal, J. Findlay, W. Ng, D.
Cowie, N. Badner, I. Herrick, H. Smith, G. Heard, R.
Peterson, J. Howell, L. Lindsey, L. Carriere, M. von
Lewinski, B. Schaefer, D. Bisnaire, P. Doyle-Pettypiece,
M. McTaggart; Keck School of Medicine at University
of Southern California, Los Angeles (51): S. Giannotta,
V. Zelman, E. Thomson, E. Babayan, C. McCleary, D.
Fishback; University of Michigan Medical Center,
Ann Arbor (41): S. Samra, B. Thompson, W. Chandler,
J. Mcgillicuddy, K. Tremper, C. Turner, P. Smythe, E.
Dy, S. Pai, V. Portman, J. Palmisano, D. Auer, M.
Quigley, B. Giordani, A. Freymuth, P. Scott, R.
Silbergleit, S. Hickenbottom; University of California
San Francisco, San Francisco (39): L. Litt, M. Lawton,
L. Hannegan, D. Gupta, P. Bickler, B. Dodson, P. Talke,
I. Rampil, B. Chen, P. Wright, J. Mitchell, S. Ryan, J.
Walker, N. Quinnine, C. Applebury; Alfred Hospital,
Melbourne, Australia (35): P. Myles, J. Rosenfeld, J.
Hunt, S. Wallace, P. D’Urso, C. Thien, J. McMahon, S.
Wadanamby, K. Siu, G. Malham, J. Laidlaw, S. Salerno,
S. Alatakis, H. Madder, S. Cairo, A. Konstantatos, J.
Smart, D. Lindholm, D. Bain, H. Machlin, J. Moloney,
M. Buckland, A. Silvers, G. Downey, A. Molnar, M.
Langley, D. McIlroy, D. Daly, P. Bennett, L. Forlano, R.
Testa, W. Burnett, F. Johnson, M. Angliss, H. Fletcher;
Toronto Western Hospital, University Health Net-
work, Toronto (32): P. Manninen, M. Wallace, K.
Lukitto, M. Tymianski, P. Porter, F. Gentili, H. El-
Beheiry, M. Mosa, P. Mak, M. Balki, S. Shaikh, R. Saw-
yer, K. Quader, R. Chelliah, P. Berklayd, N. Merah, G.
Ghazali, M. McAndrews, J. Ridgley, O. Odukoya, S.
Yantha; Wake Forest University Baptist Medical Cen-
ter, Winston-Salem, N.C. (31): J. Wilson, P. Petrozza,
C. Miller, K. O’Brien, C. Tong, M. Olympio, J. Reynolds,
D. Colonna, S. Glazier, S. Nobles, D. Hill, H. Hulbert,
W. Jenkins; Mayo Clinic College of Medicine, Roches-
ter, Minn. (28): W. Lanier, D. Piepgras, R. Wilson, F.
Meyer, J. Atkinson, M. Link, M. Weglinski, K. Berge, D.
McGregor, M. Trenerry, G. Smith, J. Walkes, M.
Felmlee-Devine; West fälische Wilhelms-Universitat
Muenster, Muenster, Germany (27): H. Van Aken, C.
Greiner, H. Freise, H. Brors, K. Hahnenkamp, N.
Monteiro de Oliveira, C. Schul, D. Moskopp, J. Woelfer,
C. Hoenemann, H. Gramke, H. Bone, I. Gibmeier, S.
Wirtz, H. Lohmann, J. Freyhoff, B. Bauer; University of
Wisconsin Clinical Science Center, Madison (26): K.
Hogan, R. Dempsey, D. Rusy, B. Badie, B. Iskandar, D.
Resnick, P. Deshmukh, J. Fitzpatrick, F. Sasse, T.
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N. Page, B. Hermann, J. Jones, D. Dulli, H. Stanko, M.
Geraghty, R. Elbe; Montreal Neurological Hospital,
Montreal (24): F. Salevsky, R. Leblanc, N. Lapointe, H.
Macgregor, D. Sinclair, D. Sirhan, M. Maleki, M. Abou-
Madi, D. Chartrand, M. Angle, D. Milovan, Y.
Painchaud; Johns Hopkins Medical Institutions, Balti-
more (23): M. Mirski, R. Tamargo, S. Rice, A. Olivi, D.
Kim, D. Rigamonti, N. Naff, M. Hemstreet, L. Berkow, P.
Chery, J. Ulatowski, L. Moore, T. Cunningham, N.
McBee, T. Hartman, J. Heidler, A. Hillis, E. Tuffiash, C.
Chase, A. Kane, D. Greene-Chandos, M. Torbey, W.
Ziai, K. Lane, A. Bhardwaj, N. Subhas; Cleveland Clinic
Foundation, Cleveland (20): A. Schubert, M. Mayberg,
M. Beven, P. Rasmussen, H. Woo, S. Bhatia, Z. Ebrahim,
M. Lotto, F. Vasarhelyi, J. Munis, K. Graves, J. Woletz,
G. Chelune, S. Samples, J. Evans, D. Blair, A. Abou-
Chebl, F. Shutway, D. Manke, C. Beven; New York Pres-
byterian Hospital–Weill Medical College of Cornell
University, New York (15): P. Fogarty-Mack, P. Stieg,
R. Eliazo, P. Li, H. Riina, C. Lien, L. Ravdin, J. Wang, Y.
Kuo; Stanford University Medical Center, Palo Alto,
Calif. (15): R. Jaffe, G. Steinberg, D. Luu, S. Chang, R.
Giffard, H. Lemmens, R. Morgan, A. Mathur, M. Angst,
A. Meyer, H. Yi, P. Karzmark, T. Bell-Stephens, M.
Marcellus; Plymouth Hospitals National Health Ser-
vice Trust, Plymouth, United Kingdom (14): J. Sneyd,
L. Pobereskin, S. Salsbury, P. Whitfield, R. Sawyer, A.
Dashfield, R. Struthers, P. Davies, A. Rushton, V. Petty,
S. Harding, E. Richardson; University of Pittsburgh
Medical Center, Pittsburgh (11): H. Yonas, F. Gyulai,
L. Kirby, A. Kassam, N. Bircher, L. Meng, J. Krugh, G.
Seever, R. Hendrickson, J. Gebel; Austin Health, Mel-
bourne, Australia (10): D. Cowie, G. Fabinyi, S. Poustie,
G. Davis, A. Drnda, D. Chandrasekara, J. Sturm, T. Phan,
A. Shelton, M. Clausen, S. Micallef; Methodist Univer-
sity Hospital, Memphis, Tenn. (8): A. Sills, F.
Steinman, P. Sutton, J. Sanders, D. Van Alstine, D.
Leggett, E. Cunningham, W. Hamm, B. Frankel, J.
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sity of Alabama at Birmingham, Birmingham (7): S.
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